CEO Ceesay Abraham sold 76,420 shares (~62.4% of holdings) at $26.30–$27.04 on 2025-09-17 for $2,011,197.18.
Ceesay Abraham, Chief Executive Officer of Rapport Therapeutics, executed 4 separate sales totaling 76,420 shares for $2,011,197.18 on a single trading day, reducing his holdings from 122,564 shares to 46,144 shares—a reduction of 62.4% of pre-transaction holdings. The sales occurred at prices ranging from $26.30 to $27.04, near the current price of $26.36 and well below the 52-week high of $31.47. The timing coincides with a dramatic 30-day rally of +84.1% and a 90-day surge of +141.4%, suggesting the CEO executed this large reduction during a period of significant upward price momentum. Against this backdrop, the company remains fundamentally unprofitable with a net income of $-26,732,000 over its most recent full fiscal year, creating a disconnect between the stock's recent performance and underlying financial condition.